Lithium modulates the production of peripheral and cerebral cytokines in an animal model of mania induced by dextroamphetamine

Bipolar Disord. 2015 Aug;17(5):507-17. doi: 10.1111/bdi.12299. Epub 2015 Apr 30.

Abstract

Objectives: Several recent studies have suggested that the physiopathology of bipolar disorder (BD) is related to immune system alterations and inflammation. Lithium (Li) is a mood stabilizer that is considered the first-line treatment for this mood disorder. The goal of the present study was to investigate the effects of Li administration on behavior and cytokine levels [interleukin (IL)-1β, IL-4, IL-6, IL-10, and tumor necrosis factor-alpha (TNF-α)] in the periphery and brains of rats subjected to an animal model of mania induced by amphetamine (d-AMPH).

Methods: Male Wistar rats were treated with d-AMPH or saline (Sal) for 14 days; on Day 8 of treatment, the rats were administered Li or Sal for the final seven days. Cytokine (IL-1β, IL-4, IL-6, IL-10, and TNF-α) levels were evaluated in the cerebrospinal fluid (CSF), serum, frontal cortex, striatum, and hippocampus.

Results: The present study showed that d-AMPH induced hyperactivity in rats (p < 0.001), and Li treatment reversed this behavioral alteration (p < 0.001). In addition, d-AMPH increased the levels of IL-4, IL-6, IL-10, and TNF-α in the frontal cortex (p < 0.001), striatum (p < 0.001), and serum (p < 0.001), and treatment with Li reversed these cytokine alterations (p < 0.001).

Conclusions: Li modulates peripheral and cerebral cytokine production in an animal model of mania induced by d-AMPH, suggesting that its action on the inflammatory system may contribute to its therapeutic efficacy.

Keywords: amphetamine; bipolar disorder; cytokines; lithium; mania.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antimanic Agents / pharmacology*
  • Antimanic Agents / therapeutic use
  • Behavior, Animal / drug effects*
  • Bipolar Disorder / chemically induced
  • Bipolar Disorder / drug therapy
  • Bipolar Disorder / immunology*
  • Brain / drug effects*
  • Brain / immunology
  • Central Nervous System Stimulants / toxicity
  • Cytokines / cerebrospinal fluid
  • Cytokines / drug effects*
  • Cytokines / immunology
  • Dextroamphetamine / toxicity
  • Disease Models, Animal
  • Frontal Lobe / drug effects
  • Frontal Lobe / immunology
  • Hippocampus / drug effects
  • Hippocampus / immunology
  • Hyperkinesis / chemically induced
  • Hyperkinesis / drug therapy
  • Hyperkinesis / immunology
  • Interleukin-10 / cerebrospinal fluid
  • Interleukin-10 / immunology
  • Interleukin-1beta / cerebrospinal fluid
  • Interleukin-1beta / drug effects
  • Interleukin-1beta / immunology
  • Interleukin-4 / cerebrospinal fluid
  • Interleukin-4 / immunology
  • Interleukin-6 / cerebrospinal fluid
  • Interleukin-6 / immunology
  • Lithium Compounds / pharmacology*
  • Lithium Compounds / therapeutic use
  • Male
  • Motor Activity / drug effects*
  • Motor Activity / immunology
  • Neostriatum / drug effects
  • Neostriatum / immunology
  • Rats
  • Rats, Wistar
  • Tumor Necrosis Factor-alpha / cerebrospinal fluid
  • Tumor Necrosis Factor-alpha / drug effects
  • Tumor Necrosis Factor-alpha / immunology

Substances

  • Antimanic Agents
  • Central Nervous System Stimulants
  • Cytokines
  • IL1B protein, rat
  • Interleukin-1beta
  • Interleukin-6
  • Lithium Compounds
  • Tumor Necrosis Factor-alpha
  • Interleukin-10
  • Interleukin-4
  • Dextroamphetamine